Trial
NCT03617484
Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Michigan Rogel Cancer Center
Collaborators
—
Condition
Mantle Cell Lymphoma
Intervention
Bortezomib
Why stopped
Enrollment and/or interactions/interventions temporarily paused due to COVID-19 and expected to resume in the future. This is not a suspension of IRB approval.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-06-22